 |
|
|
| |
BMS-986036 (PEGylated FGF21) in Patients with Non-Alcoholic Steatohepatitis: A Phase 2 Study
|
| |
| |
Reported by Jules Levin
The Liver Meeting, American Association for the Study of Liver Diseases (AASLD 2017)Washington, DC, October 20-24, 2017
Arun Sanyal,1Edgar D. Charles,2 Brent Neuschwander-Tetri,3Rohit Loomba,4Stephen Harrison,5Manal F. Abdelmalek,6Eric Lawitz,7Dina Halegoua-DeMarzio,8YupingDong,2Stephanie Noviello,2Yi Luo,2Rose Christian2
1Virginia Commonwealth University, Richmond, Virginia, USA; 2Bristol-Myers Squibb, Lawrenceville, New Jersey, USA;3Saint Louis University, Saint Louis, Missouri, USA; 4University of California -San Diego, San Diego, California, USA; 5Pinnacle Clinical Research, San Antonio, Texas, USA; 6Duke University, Durham, North Carolina, USA; 7Texas Liver Institute, University of Texas Health, San Antonio, Texas, USA; 8Thomas Jefferson University, Philadelphia, Pennsylvania, USA
|
| |
|
|
|
|
|
